date:Apr 26, 2012
the agency before taking their products to market.
In a statement, the FDA said that it is investing in a nanotechnology regulatory science program to further enhance FDAs scientific capabilities, including developing necessary data and tools to identify properties of nanomaterials and assess the impact they may have on products.
FDA Commissioner Margaret A. Hamburg said, Understanding nanotechnology remains a top FDA priority. We are taking a prudent scientific approach to assess each p